LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS : vimarsana.com

Q4 Business and Financial Highlights: Net Sales were $74.2 Million Adjusted Gross Margin Better than Expected, Improved vs Q3 Cash Was $88 Million at June 30...

Related Keywords

United States , Canada , Robert Jaffe , Flovent Diskus , Andas To Chartwell Inc , Glaxosmithkline , Lannett Company , Cediprof Inc , Prnewswire Lannett Company Inc , Boehringer Ingelheim , Exchange Commission , Recro Gainesville , Lannett Company Inc , Robert Jaffe Co , Financial Highlights , Gross Margin Better , Major Elements , Biosimilar Insulin Glargine Clinical Trial Over , Top Line Results Anticipated , Year End , First Half , Biosimilar Insulin Aspart , Product On Track , Early Next Calendar Year , Commence Pilot , Mesalamine Delayed Release Tablets , Tim Crew , Pipeline Update Subject , Biologics License Application , Cost Reduction , Quarter Financial Results , Year Financial Results , Call Information , Private Securities Litigation Reform Act , Biologics License Applications , Chief Information Officer ,